NASDAQ:NVCR NovoCure (NVCR) Stock Price, News & Analysis → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Free NVCR Stock Alerts $12.23 -0.11 (-0.89%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$11.88▼$12.3750-Day Range$11.83▼$17.2952-Week Range$10.87▼$83.60Volume1.15 million shsAverage Volume1.34 million shsMarket Capitalization$1.32 billionP/E RatioN/ADividend YieldN/APrice Target$31.13 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get NovoCure alerts: Email Address NovoCure MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.56 Rating ScoreUpside/Downside154.5% Upside$31.13 Price TargetShort InterestBearish6.27% of Float Sold ShortDividend StrengthN/ASustainability-1.15Upright™ Environmental ScoreNews Sentiment0.07Based on 6 Articles This WeekInsider TradingSelling Shares$127,161 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.78) to ($1.84) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.13 out of 5 starsMedical Sector122nd out of 907 stocksSurgical & Medical Instruments Industry20th out of 96 stocks 4.3 Analyst's Opinion Consensus RatingNovoCure has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on 5 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageNovoCure has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.27% of the float of NovoCure has been sold short.Short Interest Ratio / Days to CoverNovoCure has a short interest ratio ("days to cover") of 4.8.Change versus previous monthShort interest in NovoCure has recently increased by 20.56%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldNovoCure does not currently pay a dividend.Dividend GrowthNovoCure does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreNovoCure has received a 68.17% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for cancer", "Brain cancer medication", and "Cabozantinib" products. See details.Environmental SustainabilityThe Environmental Impact score for NovoCure is -1.15. Previous Next 2.3 News and Social Media Coverage News SentimentNovoCure has a news sentiment score of 0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for NovoCure this week, compared to 5 articles on an average week.Search Interest9 people have searched for NVCR on MarketBeat in the last 30 days. This is an increase of 80% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added NovoCure to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NovoCure insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $127,161.00 in company stock.Percentage Held by InsidersOnly 5.67% of the stock of NovoCure is held by insiders.Percentage Held by Institutions84.61% of the stock of NovoCure is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for NovoCure are expected to decrease in the coming year, from ($1.78) to ($1.84) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NovoCure is -6.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NovoCure is -6.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNovoCure has a P/B Ratio of 3.61. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> About NovoCure Stock (NASDAQ:NVCR)NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.Read More NVCR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NVCR Stock News HeadlinesApril 25, 2024 | americanbankingnews.comNovoCure (NASDAQ:NVCR) Share Price Passes Below 50 Day Moving Average of $14.57April 25, 2024 | americanbankingnews.comNovoCure (NVCR) Scheduled to Post Earnings on ThursdayApril 25, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.April 24, 2024 | finance.yahoo.comResults of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024April 24, 2024 | businesswire.comResults of Novocure's METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024April 11, 2024 | markets.businessinsider.comBuy Rating on NovoCure: Promising METIS Therapy and Strategic Commercial ExecutionApril 5, 2024 | businesswire.comNovocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024April 3, 2024 | markets.businessinsider.comNovoCure (NVCR) Receives a Buy from Wells FargoApril 25, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.April 1, 2024 | finance.yahoo.comNovocure to Report First Quarter 2024 Financial ResultsMarch 30, 2024 | fool.comWhy NovoCure Stock Soared 18.3% This WeekMarch 29, 2024 | markets.businessinsider.comNovoCure’s TTFields Show Promise in METIS Study: Outperform Rating Reaffirmed with Raised Price TargetMarch 28, 2024 | fool.comWhy Novocure Stock Is Jumping TodayMarch 27, 2024 | seekingalpha.comNovoCure: Sell The METIS-Inspired RallyMarch 27, 2024 | markets.businessinsider.comNuanced Phase 3 Results Prompt Cautious Hold Rating for NovoCure’s StockMarch 27, 2024 | msn.comNovocure's device shown to slow cancer progression in the brain in trialMarch 27, 2024 | markets.businessinsider.comPeeling Back The Layers: Exploring NovoCure Through Analyst InsightsMarch 27, 2024 | marketwatch.comNovocure’s stock surges after positive results in brain-cancer trialMarch 27, 2024 | markets.businessinsider.comNovocure Shares Rise After Phase 3 METIS Trial Met Primary EndpointMarch 27, 2024 | msn.comNovocure Stock Soars, Its Lung Cancer Electric Field Treatment Slows Progression To Brain, Data ShowsMarch 27, 2024 | proactiveinvestors.comNovoCure device slows spread of lung cancer to brain in late-stage study; shares riseMarch 27, 2024 | marketwatch.comNovocure Shares Surge Premarket on Phase 3 TTFields StudyMarch 27, 2024 | investing.comNovocure shares jump after trial meets primary endpointMarch 27, 2024 | msn.comNovocure's lung cancer therapy succeeds in late-stage trialMarch 27, 2024 | businesswire.comZai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung CancerMarch 27, 2024 | businesswire.comMETIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung CancerMarch 20, 2024 | finance.yahoo.comNVCR Dec 2025 17.500 callSee More Headlines Receive NVCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NovoCure and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/22/2024Today4/25/2024Next Earnings (Confirmed)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:NVCR CUSIPN/A CIK1645113 Webwww.novocure.com Phone441534756700FaxN/AEmployees1,453Year FoundedN/APrice Target and Rating Average Stock Price Target$31.13 High Stock Price Target$51.00 Low Stock Price Target$15.00 Potential Upside/Downside+154.5%Consensus RatingModerate Buy Rating Score (0-4)2.56 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($1.95) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-207,040,000.00 Net Margins-40.65% Pretax Margin-37.65% Return on Equity-51.63% Return on Assets-17.90% Debt Debt-to-Equity Ratio1.57 Current Ratio5.78 Quick Ratio5.56 Sales & Book Value Annual Sales$509.34 million Price / Sales2.58 Cash FlowN/A Price / Cash FlowN/A Book Value$3.39 per share Price / Book3.61Miscellaneous Outstanding Shares107,606,000Free Float101,505,000Market Cap$1.32 billion OptionableOptionable Beta0.42 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. William F. Doyle (Age 62)Executive Chairman Comp: $1.52MMr. Asaf Danziger (Age 58)CEO & Director Comp: $1.7MMs. Ashley Cordova (Age 45)Chief Financial Officer Comp: $933.39kMr. Wilhelmus C. M. Groenhuysen (Age 66)Chief Operating Officer Comp: $1.01MMr. Frank LeonardExecutive VP & President of Novocure OncologyProf. Yoram Palti M.D. (Age 86)Ph.D., Founder & CTO Comp: $282.51kDr. Moshe Giladi Ph.D. (Age 54)Chief Science Officer Ms. Ingrid GoldbergVP of Investor RelationsMr. Barak Ben Arye (Age 47)General Counsel Mr. Michael Puri (Age 55)Chief Human Resources Officer More ExecutivesKey CompetitorsLeMaitre VascularNASDAQ:LMATAtriCureNASDAQ:ATRCMiMedx GroupNASDAQ:MDXGArtivionNYSE:AORTParagon 28NYSE:FNAView All CompetitorsInsiders & InstitutionsSimplex Trading LLCSold 2,100 shares on 4/25/2024Ownership: 0.000%Taylor Frigon Capital Management LLCBought 30,057 shares on 4/19/2024Ownership: 0.118%Counterpoint Mutual Funds LLCBought 19,489 shares on 4/15/2024Ownership: 0.044%GAMMA Investing LLCBought 2,118 shares on 4/5/2024Ownership: 0.003%Vanguard Group Inc.Bought 122,105 shares on 3/11/2024Ownership: 9.113%View All Insider TransactionsView All Institutional Transactions NVCR Stock Analysis - Frequently Asked Questions Should I buy or sell NovoCure stock right now? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NovoCure in the last twelve months. There are currently 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" NVCR shares. View NVCR analyst ratings or view top-rated stocks. What is NovoCure's stock price target for 2024? 9 brokers have issued 1-year price targets for NovoCure's stock. Their NVCR share price targets range from $15.00 to $51.00. On average, they expect the company's stock price to reach $31.13 in the next year. This suggests a possible upside of 154.5% from the stock's current price. View analysts price targets for NVCR or view top-rated stocks among Wall Street analysts. How have NVCR shares performed in 2024? NovoCure's stock was trading at $14.93 at the start of the year. Since then, NVCR stock has decreased by 18.1% and is now trading at $12.23. View the best growth stocks for 2024 here. Are investors shorting NovoCure? NovoCure saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 6,040,000 shares, an increase of 20.6% from the March 31st total of 5,010,000 shares. Based on an average trading volume of 1,270,000 shares, the short-interest ratio is presently 4.8 days. Approximately 6.3% of the shares of the company are sold short. View NovoCure's Short Interest. When is NovoCure's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our NVCR earnings forecast. How can I listen to NovoCure's earnings call? NovoCure will be holding an earnings conference call on Thursday, May 2nd at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link. How were NovoCure's earnings last quarter? NovoCure Limited (NASDAQ:NVCR) announced its quarterly earnings results on Thursday, February, 22nd. The medical equipment provider reported ($0.45) EPS for the quarter, beating the consensus estimate of ($0.53) by $0.08. The medical equipment provider earned $133.80 million during the quarter, compared to analyst estimates of $133.80 million. NovoCure had a negative trailing twelve-month return on equity of 51.63% and a negative net margin of 40.65%. NovoCure's revenue for the quarter was up 4.2% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.36) earnings per share. What ETFs hold NovoCure's stock? ETFs with the largest weight of NovoCure (NASDAQ:NVCR) stock in their portfolio include Counterpoint Quantitative Equity ETF (CPAI) and Amplify BlueStar Israel Technology ETF (ITEQ).iShares U.S. Medical Devices ETF (IHI). What is Asaf Danziger's approval rating as NovoCure's CEO? 17 employees have rated NovoCure Chief Executive Officer Asaf Danziger on Glassdoor.com. Asaf Danziger has an approval rating of 90% among the company's employees. What other stocks do shareholders of NovoCure own? Based on aggregate information from My MarketBeat watchlists, some companies that other NovoCure investors own include Chembio Diagnostics (CEMI), Prospect Capital (PSEC), Calumet Specialty Products Partners (CLMT), NVIDIA (NVDA), Two Harbors Investment (TWO), BlackRock Capital Investment (BKCC), Viper Energy (VNOM), Roku (ROKU), Salesforce (CRM) and Block (SQ). Who are NovoCure's major shareholders? NovoCure's stock is owned by many different institutional and retail investors. Top institutional shareholders include Taylor Frigon Capital Management LLC (0.12%), Simplex Trading LLC (0.00%), Counterpoint Mutual Funds LLC (0.04%) and GAMMA Investing LLC (0.00%). Insiders that own company stock include Asaf Danziger, Ashley Cordova, Ely Benaim, Frank X Leonard, Frank X Leonard, Gabriel Leung, Jeryl L Hilleman, Martin J Madden, Pritesh Shah, Todd Christopher Longsworth, Uri Weinberg, Wilhelmus Cm Groenhuysen and William F Doyle. View institutional ownership trends. How do I buy shares of NovoCure? Shares of NVCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NVCR) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsJim Cramer’s “The Biggest Drug Ever”Behind the MarketsYour Money is Not SafeAmerican AlternativeThe AI stock to buy right nowStockEarningsThe only accurate crypto trading system I know …Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NovoCure Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
